Technojet Consultants reported a net loss of ₹2.57 lakh for the quarter ended June 30, 2026, widening from a loss of ₹1.97 lakh in the corresponding period of the previous year. Total income from operations for Q1FY26 stood at ₹2.20 lakh, compared to ₹0.62 lakh in Q1FY25. The company's financial performance reflects continued pressure on profitability as total expenses outpaced income during the period.

The Board of Directors approved the unaudited financial results at a meeting held on July 15, 2026. The results were reviewed by the Audit Committee and subsequently approved by the Board. The financial statements were prepared in accordance with Indian Accounting Standard (Ind AS) 34 and comply with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The extract of the results was published in Business Standard and Pratahkal on July 17, 2026.

Financial Performance

The company's total income for Q1FY26 rose to ₹2.20 lakh from ₹0.62 lakh in the same period last year. However, the net loss for the period before tax widened to ₹2.57 lakh from ₹1.97 lakh in Q1FY25. There were no exceptional items reported during the quarter. The earnings per share (EPS) for the quarter stood at a loss of ₹1.28 on a basic and diluted basis.

Key Financial Metrics (₹ in Lakh)

The paid-up equity share capital remained unchanged at ₹20 lakh, comprising 200,000 equity shares of ₹10 each fully paid-up. Other equity was nil for the quarter. The company stated there are no reportable segments as per Ind AS 108, 'Operating Segment'. The full format of the financial results is available on the BSE website and the company's website.

Technojet Consultants Limited reported a net loss of ₹10.87 lakh for the financial year ended March 31, 2026, a reversal from the net profit of ₹3.73 lakh recorded in the previous year. The company’s total income for the year stood at ₹3.14 lakh, while total expenses amounted to ₹12.99 lakh. Despite the loss, the Board of Directors has recommended a dividend of ₹87 per equity share of ₹10 each, subject to the approval of shareholders at the 44th Annual General Meeting scheduled for June 19, 2026.

The financial results indicate that the company did not generate revenue from operations during the year under review, compared to ₹12 lakh in the previous year. Other income, which includes interest and profit on the sale of investments, was ₹3.14 lakh. The statement of profit and loss shows a profit before tax of ₹(9.85) lakh, with a tax expense of ₹1.02 lakh relating to an earlier period. The company’s balance sheet reflects total assets of ₹212.16 lakh, with cash and cash equivalents constituting a significant portion at ₹202.95 lakh.

Dividend and AGM Details

The proposed dividend of ₹87 per share will be paid to shareholders whose names appear on the Register of Members as of the record date, June 12, 2026. The register of members will remain closed from June 13, 2026, to June 19, 2026. The Annual General Meeting will be held at the company’s registered office in Mumbai. The notice for the AGM also includes the re-appointment of Director Mr. Jairaj Champaklal Bham, who retires by rotation and is eligible for re-appointment.

Financial Performance

The auditors, M/s. Manek & Associates, stated that the company used accounting software with an audit trail feature throughout the year. The Independent Auditor’s Report highlighted the valuation and sale of equity shares classified as Fair Value Through Other Comprehensive Income (FVTOCI) as a key audit matter. The company sold 48,000 equity shares of INOR Medical Products Limited during the year.